Hypertriglyceridemia in bone marrow transplant recipients: another side effect of cyclosporine A

Bone Marrow Transplant. 1989 Jul;4(4):385-8.

Abstract

The incidence and duration of hypertriglyceridemia (HTG) associated with allogeneic HLA-identical bone marrow transplantation (BMT) were investigated in 38 patients with normal triglyceride levels (TG) before BMT and without any evidence of prior liver disorder. Twenty-two (58%) patients developed HTG. The median of TG peak values was 350 mg/dl (range 215-908) and the median actuarial time for HTG appearance was 7 weeks (range 1-12). Among several variables analysed (age, sex, hyperglycemia, total parenteral nutrition, treatment with methylprednisolone, estrogens or cyclosporine A) only cyclosporine A administration was significantly associated with HTG development.

MeSH terms

  • Adolescent
  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Cyclosporins / adverse effects
  • Cyclosporins / therapeutic use*
  • Female
  • HLA Antigens / immunology
  • Histocompatibility
  • Humans
  • Hypertriglyceridemia / etiology*
  • Hypertriglyceridemia / pathology
  • Immunosuppressive Agents / adverse effects
  • Male
  • Transplantation, Homologous

Substances

  • Cyclosporins
  • HLA Antigens
  • Immunosuppressive Agents